|
Support for Prostate Screening, ECR Attendance, and Ultrasound in Space
March 16, 2026
|
|
|
|
|
Together with
|
|
|
|
“[I]f prostate cancer screening were extended to the wider population, then the outcomes are likely to be very similar to breast cancer.”
|
|
Sigrid Carlsson, MD, PhD, of DKFZ German Cancer Research Center on new results from the PROBASE study.
|
|
|
|
Routine prostate cancer screening currently isn’t supported by clinical guidelines. But that could be changing, especially given research presented this week finding that prostate screening – aided by MRI to reduce unnecessary biopsies – was as effective as mammography screening.
Prostate cancer is one of the leading causes of cancer death, killing some 360k men worldwide every year.
- But efforts to develop effective prostate cancer screening programs have been hampered by the challenges inherent in PSA testing, which often identifies indolent disease that may never pose a health risk to patients – the classic definition of overdiagnosis.
That could be starting to change, however. Researchers are discovering that using MRI to work up patients with rising PSA levels could help identify men with high-risk disease who should be sent to biopsy, while lower-risk patients are monitored with surveillance.
- New research presented at the European Association of Urology meeting on Sunday supports this idea, showing that – if done right – prostate cancer screening can be as effective as mammography screening.
Researchers from Germany compared prostate cancer screening data from 39.4k men who got PSA tests as part of the PROBASE trial to over 2.8M women who participated in the country’s national breast cancer screening program.
- Under the PROBASE protocol, men with confirmed PSA levels ≥ 3 ng/mL underwent MRI and biopsy, while those with lower PSA levels got repeat PSA testing in an effort to keep biopsy rates lower.
Major findings of the study included…
- Both breast and prostate screening detected a high rate of clinically significant, invasive cancers (73% for mammography vs. 69% for 45-year-old men and 74% for 50-year-old men).
- False-positive rates were much lower for breast screening (10% vs. 42% and 37%).
- And fewer indolent cancers were detected with mammography (22% vs. 31% and 26%).
- But biopsy rates were comparable (1.1% vs. 0.8% and 2.4%), as the study’s active surveillance protocol limited over-treatment.
While the PROBASE study didn’t use AI as part of its protocol, other research has found that AI analysis of MRI scans can make the modality even more precise, with the PI-CAI study just one worth noting.
The Takeaway
Is it finally time for prostate cancer screening to join breast, colorectal, cervical, and lung among the major population-based cancer screening tests? Results from the PROBASE study at EAU 2026 suggest the time may finally be right.
|
|
Next-Generation 1.5T MRI
Echelon Synergy from Fujifilm Healthcare Americas is a powerful and affordable next-generation 1.5T MRI system featuring Synergy DLR deep-learning reconstruction, fast exam times, and patient-friendly design. Discover how it can help you achieve faster workflow and improved image quality.
|
|
The Workstation of the Future
A dedicated team of radiologists shapes every aspect of the functionality and design of MosaicOS from Mosaic Clinical Technologies. Learn how every feature was built to eliminate distractions, amplify focus, and enhance the radiologist experience.
|
|
Driving Efficiency in Radiology
Radiology’s workforce is under pressure. Discover evidence-based strategies for driving efficiency without burning out your staff in this e-book from Riverain Technologies.
|
|
- Prostate Screening Reduces Cancer Mortality: Another study from EAU 2026 showed that screening reduced long-term prostate cancer mortality in Sweden. Some 10k men were screened with PSA tests every two years and tracked over 30 years. Screening averted one death for every 311 men invited over 15 years and one for every 161 men over 30 years, showing a growing beneficial impact over time. The numbers are comparable to mammography, and it’s worth noting that the study didn’t use MRI to reduce overdiagnosis.
- PSMA-PET Could Cut Prostate Biopsies: While MRI is most commonly used to work up men suspected of having prostate cancer, new findings from the PRIMARY2 trial at EAU 2026 show PSMA-PET/CT could also fill that role. In 600 men with suspected prostate cancer, some men got PSMA-PET/CT scans, and those with higher risk scores were sent to biopsy. Prostate biopsies were avoided in 49% of PSMA-PET patients, with lower diagnosis rates of clinically insignificant cancer compared to control patients (14% vs. 32%).
- Experts Support MRI-Guided Prostate Screening: The clinical community seems to be coalescing around how to use MRI as part of prostate cancer screening. The PRISM recommendations presented at EAU 2026 cover 300 statements on how to use MRI in screening programs. Separately, data from the PRAISE-U study at the conference showed that MRI referrals can be reduced by 40%-60% when risk stratification is used in addition to PSA levels, while the Stockholm3 trial used a blood biomarker test to reduce MRI referrals by 67% and biopsies by 40%.
- FDA Approves New Pylarify Formulation: The FDA approved a new formulation of the Pylarify PSMA-PET radiotracer for prostate cancer imaging from Lantheus. Pylarify TruVu has the same diagnostic properties as the original formulation of Pylarify, but is more stable at higher radioactive concentrations, which makes manufacturing and distribution more efficient. Lantheus expects the formulation to support larger batch sizes, which enables manufacturing sites with high-energy cyclotrons to reach more patients across a broader geographic area.
- Prostate Cancer Deaths to Drop: A new research overview highlights progress in reducing prostate cancer mortality, thanks to improved screening. In the U.S. from 1992 to 2024, increased PSA testing boosted prostate cancer detection 58% and reduced annual deaths 15%. Mortality rates per 100k cases fell from 1999 to 2020 (from 90 to 53), but the decline slowed after 2013. Also, the number of annual U.S. deaths has stayed flat despite a growing population of elderly men – a sign screening is working.
- Esaote Debuts Prostate Ultrasound Tool: Esaote is taking advantage of EAU 2026 to launch a new ultrasound tool for prostate cancer imaging. The company’s Prostate Attenuation Map feature provides automated analysis of prostate multiparametric MRI volumes to help urologists visualize suspicious regions of interest and to guide prostate biopsy procedures. PAM is part of Esaote’s UroFusion software on its new MyLab E85 GTS scanner, which is part of the GTS line that Esaote launched at ECR 2026.
- Location Affects Breast Cancer Diagnosis: A new paper underscores disturbing disparities in breast cancer diagnosis, finding advanced-stage diagnoses more common in rural areas. Researchers analyzed data from 52.3k U.S. women, finding rates of Stage 3 or 4 diagnoses more common among rural women (14% vs. 12%). Odds of a Stage 4 diagnosis were 34% higher for women in the East South Central region (Alabama, Kentucky, Mississippi, Tennessee) and 33% higher in the West South Central (Arkansas, Louisiana, Oklahoma, Texas). Minority women also had higher rates of advanced disease.
- RamSoft Shows Updated PowerServer at HIMSS: RamSoft debuted an updated version of its PowerServer image management software at HIMSS 2026. PowerServer 6.7 includes performance enhancements that enable 80% faster image viewing for major modalities compared to the previous version. The new version also includes support for AI orchestration to improve radiology workflow, with integrated capabilities that support AI-based worklist, clinical AI orchestration, and reporting, as well as scheduling, eligibility, and prior authorization.
- Record Attendance at ECR: Attendance at ECR 2026 hit an all-time high, despite travel disruptions that prevented many radiology professionals from the Middle East from attending the event. The European Society of Radiology reported that onsite and online attendance hit 22.4k, up 9% from ECR 2025. Of the totals, 15.1k were professional attendees, while 7.3k were vendors. Italy sent the most attendees (1.5k), followed by Germany (1.2k) and Austria (841).
- United Imaging’s ECR Highlights: United Imaging highlighted a range of new technologies at ECR 2026, with their new uSonique ultrasound line leading the charge. In CT, United showed its uCT SiriuX scanner with a twin-ring gantry as a work-in-progress (not yet CE Marked), while the uMR Ultra 3T MRI scanner and uMI Panvivo PET/CT family rounded out United’s display of big iron. The vendor’s United Imaging Intelligence digital subsidiary showed its uAI Clinical Portal with 30 AI applications, as well as the uAI Insight Imaging-to-Report AI agent.
- NASA Tests AR-Guided Ultrasound in Space: Astronauts on the International Space Station this month tested an experimental ultrasound protocol guided by augmented reality. NASA’s EchoFinder-2 protocol combines a Sonoscanner portable ultrasound device with AR and AI software to enable non-expert astronauts to perform scans in space and transmit the data to Earth for review. Astronauts this month performed AR-guided scans of each other’s abdomen and vascular system. A space station mission had to be terminated early in January when an astronaut fell ill.
|
|
One Viewer for All
Achieve ultrafast image interpretation with greater efficiency and precision with Visage 7 from Visage Imaging. Visage’s one-viewer philosophy enables all end users – from radiologists to clinicians – to access powerful tools based on clinical need.
|
|
More Than a Migration: Future-Proofing Your Reporting
A reporting platform swap shouldn’t disrupt patient care. Join Rad AI on March 25 for a deep dive into navigating the PS360 end-of-life. We’ll help imaging leaders manage operational hurdles and build a roadmap for a seamless transition.
|
|
5 Data Migration Myths You May Still Believe
Many healthcare organizations fall victim to data migration myths that derail their efforts, waste valuable resources, and put their business at risk. Learn about five common myths and how they cost you in this article from Laitek, an Enlitic portfolio company.
|
|
- Cutting-Edge PET/CT to Support Theranostics: Theranostics is an exciting new field that combines diagnostics and therapy. Discover how Florida Theranostics is using United Imaging’s uMI Panorama PET/CT scanner to establish a high-quality level of patient care.
- Explore the Philips MRI App: Discover clinical cases at your fingertips, find MR solutions for your needs, enhance your diagnostic skills, and unlock insights and information, all in one place. Available on the Apple or Google app stores.
- Radiology Case Report: A man in his 40s presented with a known metastasis within his abdomen. Learn how contrast-enhanced MRI helped to diagnose the extent of his disease.
- Cardiac CT Online Training Course: Medality’s online cardiac CT training course is designed for busy clinicians working towards Level 2 Cardiac CT certification. Endorsed by SCCT, it provides a flexible, practice-focused approach to develop your coronary CTA interpretation and reporting skills while earning CME.
- The Modern Way to Send and Receive Medical Images: Medicom Connect enables you to automate clinical image exchange across your healthcare ecosystem with workflows that automatically find, retrieve, and deliver images directly to the point of care, improving access and care coordination. Learn more about Medicom’s solutions today.
- Transform Imaging Data into Actionable Predictions: When you choose Quibim, you get more than a partner for detecting and diagnosing prostate cancer on MRI scans. Learn how they can help you transform imaging data into actionable predictions by booking a demo today.
- A Best in KLAS Hat Trick: AGFA HealthCare was named Best in KLAS in three enterprise imaging segments this year: PACS under 300k studies, universal viewer, and vendor-neutral archive. Find out what makes customers keep coming back on this page.
- Empowering Radiologists at the Point of Interpretation: Rad AI and RSNA Ventures have partnered to deliver trusted, peer-reviewed RSNA insights directly into the radiologist’s workflow — at the exact point of interpretation. Watch this on-demand video to find out how it can benefit your practice.
- Radiology Automation Simplified: CARPL is an enterprise-grade radiology AI validation and deployment platform with 250+ AI applications across 85+ AI vendors that empowers healthcare providers to access, assess, and securely integrate imaging AI in their practice. Book a demo today.
- A New Solution for Radiology Reporting: Sectra Reporting delivers a fully built-in, AI-enhanced reporting experience that seamlessly connects PACS imaging data and measurements through intuitive templates. Discover how it can meet your needs today.
- Discover the Difference in Fluoroscopy: Whether tableside or universal remote, fluoroscopy systems impact safety, workflow, and patient care. Discover the difference LUMINOS Q.namix R and T from Siemens Healthineers make in the industry.
- Reporting that Works the Way You Do: End-of-life announcements for reporting systems raise the question: what if reporting actually worked the way your teams do? Discover how KailoAir from Kailo Medical can help your teams move off legacy dictation tools while gaining a more intuitive, connected experience.
- AI-Powered Population Health: DeepHealth is assembling radiology’s largest portfolio of AI-enabled radiology solutions for population health. Learn more about their focus and their recent acquisition of Gleamer in this video interview.
- Your Comprehensive Guide to Workflow Orchestration: Radiology departments are dealing with climbing case volumes while their teams reach critical levels of burnout. The solution isn’t working longer hours; it’s working with smarter technology. This guide from Merge provides practical strategies for evaluating and implementing intelligent worklist management.
- A Global Customer Reach: Mach7 Technologies serves a diverse range of healthcare organizations worldwide, from large integrated delivery networks to smaller community hospitals and imaging centers. Learn what Mach7 can do for you.
- AI Echo for Pulmonary Hypertension Assessment: Pulmonary hypertension requires careful evaluation with echocardiography, but traditional manual interpretation is time-consuming. Read this paper on how Us2.ai’s AI echo technology powered a fully automated deep learning workflow.
|
|
|
|
|
